Recerca

Àrea 5

Hemato-Oncología

Factor d'impacte: mitjana: 8.51, total: 765.68

Articles de l'any 2010
Original
  • Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

    Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, Camacho F, Bea S, Hartmann E, Amador V, Hernandez L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Swerdlow SH, Pileri SA, Bosch F, Piris MA, Montserrat E, Ott G, Rosenwald A, Lopez-Guillermo A, Jares P, Serrano S, Campo E
    CANCER RES. 2010; 70: 1408-1418. IF: 7.543

  • Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma

    Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, DeLaRubia J, Lahuerta JJ, Garcia-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Blade J, SanMiguel J
    CLIN CANCER RES. 2010; 16: 3260-3269. IF: 6.747

  • Busulfan 12 mg/kg plus melphalan 140 mg/m(2) versus melphalan 200 mg/m(2) as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

    Lahuerta JJ, Mateos MV, Martinez-Lopez J, Grande C, DeLaRubia J, Rosinol L, Sureda A, Garcia-Larana J, Diaz-Mediavilla J, Hernandez-Garcia MT, Carrera D, Besalduch J, DeArriba F, Oriol A, Escoda L, Garcia-Frade J, Rivas-Gonzalez C, Alegre A, Blade J, SanMiguel JF
    HAEMATOL-HEMATOL J. 2010; 95: 1913-1920. IF: 6.416

  • Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

    Cervantes F, Lopez-Garrido P, Montero MI, Jonte F, Martinez J, Hernandez-Boluda JC, Calbacho M, Sureda A, Perez-Rus G, Nieto JB, Perez-Lopez C, Roman-Gomez J, Gonzalez M, Pereira A, Colomer D
    HAEMATOL-HEMATOL J. 2010; 95: 1317-1324. IF: 6.416

  • Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final resullts of the CSTIBES02 trial

    Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J, DelPotro E, Rivas C, Moreno MJ, Tormo M, Martin-Reina V, Sarra J, Parody R, DeOteyza JP, Bureo E, Bernal MT
    HAEMATOL-HEMATOL J. 2010; 95: 87-95. IF: 6.416

  • Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior

    Gine E, Martinez A, Villamor N, Lopez-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntanola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, Montserrat E
    HAEMATOL-HEMATOL J. 2010; 95: 1526-1533. IF: 6.416

  • Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways

    Segarra M, Lozano E, Corbera-Bellalta M, Vilardell C, Cibeira MT, Esparza J, Izco N, Blade J, Cid MC
    HAEMATOL-HEMATOL J. 2010; 95: 456-463. IF: 6.416

  • Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk

    Crowther-Swanepoel D, Broderick P, DiBernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, Dyer MJS, Matutes E, Dearden C, Sunter NJ, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan JM, Catovsky D, Houlston RS
    NAT GENET. 2010; 42: 132-0. IF: 34.284

  • Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

    Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J, Grand FH, Cross NCP
    NAT GENET. 2010; 42: 722-0. IF: 34.284

  • Incidence and Prognostic Impact of Secondary Cytogenetic Aberrations in a Series of 145 Patients with Mantle Cell Lymphoma

    Espinet B, Salaverria I, Bea S, Ruiz-Xiville N, Balague O, Salido M, Costa D, Carreras J, Rodriguez-Vicente AE, Garcia JL, Hernandez-Rivas JM, Calasanz MJ, Siebert R, Ferrer A, Salar A, Carrio A, Polo N, Garcia-Marco JA, Domingo A, Gonzalez-Barca E, Romagosa V, Marugan I, Lopez-Guillermo A, Milla F, Mate JL, Luno E, Sanzo C, Collado R, Oliver I, Monzo S, Palacin A, Gonzalez T, Sant F, Salinas R, Ardanaz MT, Font L, Escoda L, Florensa L, Serrano S, Campo E, Sole F
    GENE CHROMOSOME CANC. 2010; 49: 439-451. IF: 3.858

  • Outcome of Transplantation for Myelofibrosis

    Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroger N, Litzow MR, Marks DI, Maziarz RT, Mccarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M
    BIOL BLOOD MARROW TR. 2010; 16: 358-367. IF: 3.149

  • Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

    Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, Harousseau JL, Sonneveld P, Blade J, Orlowski RZ
    ANN HEMATOL. 2010; 89: 1133-1140. IF: 2.919

  • Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients

    Martinez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Diaz-Beya M, Cervantes F
    ANN HEMATOL. 2010; 89: 1233-1237. IF: 2.919

  • Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype

    Tefferi A, Siragusa S, Hussein K, Schwager SM, Hanson CA, Pardanani A, Cervantes F, Passamonti F
    AM J HEMATOL. 2010; 85: 14-17. IF: 2.61

  • XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia

    Guillem VM, Cervantes F, Martinez J, Alvarez-Larran A, Collado M, Camos M, Sureda A, Maffioli M, Marugan I, Hernandez-Boluda JC
    AM J HEMATOL. 2010; 85: 482-486. IF: 2.61

  • Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era

    Gutierrez-Garcia G, Colomo L, Villamor N, Arenillas L, Martinez A, Cardesa T, Garcia-Herrera A, Setoain X, Rodriguez S, Ghita G, Abrisqueta P, Gine E, Bosch F, Campo E, Montserrat E, Lopez-Guillermo A
    LEUKEMIA LYMPHOMA. 2010; 51: 1225-1232. IF: 2.397

  • Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures

    DeLarrea CF, Rosinol L, Cibeira MT, Rozman M, Rovira M, Blade J
    EUR J HAEMATOL. 2010; 85: 448-451. IF: 2.345

  • Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma

    Ludwig H, Bolejack V, Crowley J, Blade J, SanMiguel J, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westin J, Sonneveld P, Cavo M, Boccadoro M, Palumbo A, Tosi P, Harousseau JL, Attal M, Barlogie B, Stewart AK, Durie B
    J CLIN ONCOL. 2010; 28: 1599-1605. IF: 17.793

  • Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom

    Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, DePaz R, Garcia-Larana J, Bengoechea E, Martin A, Mediavilla JD, Palomera L, DeArriba F, Gonzalez Y, Hernandez JM, Sureda A, Bello JL, Bargay J, Penalver FJ, Ribera JM, Martin-Mateos ML, Garcia-Sanz R, Cibeira MT, Ramos MLM, Vidriales MB, Paiva B, Montalban MA, Lahuerta JJ, Blade J, SanMiguel JF
    LANCET ONCOL. 2010; 11: 934-941. IF: 14.47

  • Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

    Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Perez-Andreu V, Hernandez-Boluda JC, Ayats R, Salvador C, Muntanola A, Bellosillo B, Vicente V, Hernandez-Nieto L, Burgaleta C, Xicoy B, Besses C
    BLOOD. 2010; 116: 1205-1210. IF: 10.555

  • A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

    Sanchez-Espiridion B, Montalban C, Lopez A, Menarguez J, Sabin P, Ruiz-Marcellan C, Ramos R, Rodriguez J, Canovas A, Camarero C, Canales M, Alves J, Arranz R, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sanchez-Godoy P, Burgos F, Rayon C, Fresno MF, Larana JG, Garcia-Cosio M, Santonja C, Lopez JL, Llanos M, Mollejo M, Gonzalez-Carrero J, Marin A, Forteza J, Garcia-Sanz R, Tomas JF, Morente MM, Piris MA, Garcia JF
    BLOOD. 2010; 116: 0-0. IF: 10.555

  • Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation

    Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, Tabrizi R, Nagler A, Rocha V
    BLOOD. 2010; 116: 4439-4443. IF: 10.555

  • Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance

    Moreno C, Hodgson K, Ferrer G, Elena M, Filella X, Pereira A, Baumann T, Montserrat E
    BLOOD. 2010; 116: 4771-4776. IF: 10.555

  • Thrombosis in primary myelofibrosis: incidence and risk factors

    Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larran A, Rambaldi A, Finazzi G, Barosi G
    BLOOD. 2010; 115: 778-782. IF: 10.555

  • The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status

    Diaz-Beya M, Rozman M, Pratcorona M, Torrebadell M, Camos M, Aguilar JLI, Esteve J
    BLOOD. 2010; 116: 6147-6148. IF: 10.555

  • A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

    Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A
    BLOOD. 2010; 115: 1703-1708. IF: 10.555

Revisió
  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, SanMiguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M
    LEUKEMIA. 2010; 24: 1121-1127. IF: 8.296

  • Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

    Ludwig H, Beksac M, Blade J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, SanMiguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S
    ONCOLOGIST. 2010; 15: 6-25. IF: 6.701

  • Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

    Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BGM, SanMiguel J
    J CLIN ONCOL. 2010; 28: 4976-4984. IF: 17.793

  • Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations

    Blade J, Dimopoulos M, Rosinol L, Rajkumar SV, Kyle RA
    J CLIN ONCOL. 2010; 28: 690-697. IF: 17.793

  • Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

    Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, VanDamme P, San-Miguel JF, Sonneveld P
    LANCET ONCOL. 2010; 11: 1086-1095. IF: 14.47

  • Hematopoietic stem cell transplantation for multiple myeloma beyond 2010

    Blade J, Rosinol L, Cibeira MT, Rovira M, Carreras E
    BLOOD . 2010; 115: 3655-3663. IF: 10.555

  • Current immunochemotherapy strategies in follicular lymphoma

    Gine E, Gutierrez-Garcia G, Lopez-Guillermo A
    ADV THER. 2010; 27: 704-713. IF: 0.936

Editorials
  • Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?

    Moreno C, Montserrat E
    HAEMATOL-HEMATOL J. 2010; 95: 12-15. IF: 6.416

  • Novel drugs for the treatment of multiple myeloma

    Blade J, Cibeira MT, Rosinol L
    HAEMATOL-HEMATOL J. 2010; 95: 702-704. IF: 6.416

  • Advances in Biology and Therapy of Chronic Lymphocytic Leukemia Preface

    Montserrat E
    BEST PRACT RES CL HA. 2010; 23: 1-2. IF: 3.134

  • Refining "total therapy" for myeloma

    Blade J, Rosinol L
    BLOOD. 2010; 115: 4152-4153. IF: 10.555

  • How to Treat Multiple Myeloma: Thoughts on a Multicentre Survey in Germany

    Blade J, Rosinol L, Cibeira MT, DeLarrea CF
    ONKOLOGIE. 2010; 33: 577-578. IF: 1.234

Multicèntrics
  • Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

    Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardo F, Bueno J, Grande C, DelPotro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM
    HAEMATOL-HEMATOL J. 2010; 95: 589-596. IF: 6.416

  • International network of cancer genome projects

    Hudson TJ, Anderson W, Aretz A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusuda J, Lane DP, Laplace F, Lu YY, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang HM, Yuen MMF, Knoppers M, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SOM, Joly Y, Kato K, Kennedy KL, Nicolas P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clement B, DeAlava E, Degos F, Ferguson ML, Geary P, Hayes DN, Johns AL, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, VanDeVijver M, Futreal PA, Aburatani H, Bayes M, Bowtell DDL, Campbell PJ, Estivill X, Grimmond SM, Gut I, Hirst M, Lopez-Otin C, Majumder P, Marra M, Ning ZM, Puente XS, Ruan YJ, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Flicek P, Getz G, Guigo R, Guo GW, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li QB, Lopez-Bigas N, Luo RB, Pearson JV, Quesada V, Raphael BJ, Sander C, Speed TP, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu HL, Zhao SC, Zhou GY, Stein LD, Lathrop M, Ouellette BFF, Thomas G, Yoshida T, Axton M, Gunter C, Mcpherson JD, Miller LJ, Kasprzyk A, Zhang JJ, Haider SA, Wang JX, Yung CK, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Chalmers DRC, Hasel KW, Kaan TSH, Knoppers BM, Lowrance WW, Masui T, Rodriguez LL, Vergely C, Cloonan N, Defazio A, Eshleman JR, Etemadmoghadam D, Gardiner BA, Kench JG, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Depinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Ji JF, Zhang XQ, Chen F, Hu XD, Yang Q, Tian G, Zhang LH, Xing XF, Li XH, Zhu ZG, Yu YY, Yu J, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevad L, Prokhortchouk E, Banks RE, Uhlen M, Viksna J, Ponten F, Skryabin K, Birney E, Borg A, Borresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Van'tVeer L, Birnbaum D, Blanche H, Boucher P, Boyault S, Masson-Jacquemier JD, Pauporte I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Treilleux I, Bioulac-Sage P, Decaens T, Franco D, Gut M, Samuel D, Zucman-Rossi J, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, VonKalle C, Majumder PP, Pederzoli P, Lawlor RT, Delledonne M, Bardelli A, Gress T, Klimstra D, Zamboni G, Nakamura Y, Miyano S, Fujimoto A, Campo E, DeSanjose S, Montserrat E, Gonzalez-Diaz M, Jares P, Himmelbaue H, Bea S, Aparicio S, Easton DF, Collins FS, Compton CC, Lander ES, Burke W, Green AR, Hamilton SR, Kallioniemi OP, Ley TJ, Liu ET, Wainwright BJ
    NATURE. 2010; 464: 993-998. IF: 34.48

  • Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

    Sanz MA, Montesinos P, Rayon C, Holowiecka A, DeLaSerna J, Milone G, DeLisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, Gonzalez J, Diaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, Gonzalez JD, Lowenberg B
    BLOOD. 2010; 115: 5137-5146. IF: 10.555

Guies clíniques
  • Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

    Palumbo A, Davies F, Kropff M, Blade J, Delforge M, DaCosta FL, Sanz RG, Schey S, Facon T, Morgan G, Moreau P
    ANN HEMATOL. 2010; 89: 803-811. IF: 2.919

  • Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group

    Garcia-Sanz R, Alegre A, Capote FJ, Hernandez JM, Rosinol L, DeLaRubia J, Sureda A, DeArriba F, Bargay J, Mediavilla JD, Garcia-Larana J, Lahuerta JJ, Mateos MV, Prosper F, Miguel JS, Blade J
    MED CLIN-BARCELONA. 2010; 134: 268-278. IF: 1.231

Tornar